Mediastinal Gray Zone Lymphoma: Symptoms, Treatment, Outlook

Mediastinal gray zone lymphoma (MGZL) is a rare and aggressive B-cell cancer that arises in the mediastinum, the central compartment of the chest between the lungs. It occupies a biological middle ground between two better-known lymphomas, classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, borrowing features from both without fitting neatly into either category. That overlap makes MGZL unusually difficult to diagnose and treat, and the rarity of the disease means most of the evidence guiding clinicians comes from relatively small studies rather than large randomized trials. Still, the picture of how to manage MGZL has sharpened considerably over the past decade, and outcomes for many patients are better than the “gray zone” label might suggest.

What Makes It a “Gray Zone”

The name refers to pathology, not prognosis. Under the microscope, MGZL tumor cells can look like the large Reed-Sternberg cells typical of Hodgkin lymphoma, or they can resemble the sheets of large B-cells seen in diffuse large B-cell lymphoma. Often both patterns appear in the same biopsy. The protein markers on the cell surface add to the confusion: MGZL cells commonly express CD20, a classic B-cell marker, alongside CD30, which is a hallmark of Hodgkin lymphoma. Many cases also express CD15, another Hodgkin-associated marker, creating a profile that does not match either parent disease cleanly.¹ The current international classification systems recognize MGZL as its own entity, restricted to tumors arising in the mediastinum that are negative for Epstein-Barr virus.²

Within this diagnosis, pathologists sometimes distinguish cases that lean more toward Hodgkin-like morphology from those that lean more toward large B-cell lymphoma-like morphology. The Hodgkin-leaning cases tend to show pleomorphic tumor cells scattered in a background of inflammatory cells and fibrous tissue, while the B-cell-leaning cases have denser sheets of large, more uniform tumor cells with less surrounding inflammation.³ This distinction matters because it can influence which treatment approach oncologists favor, though no clear consensus exists on whether morphological subtype should dictate therapy.

Symptoms and How the Disease Typically Presents

MGZL tends to strike younger adults, often in their twenties and thirties, and it does not have a strong sex predominance. Because the tumor grows in the mediastinum, many of the initial symptoms come from a mass pressing on surrounding structures. Shortness of breath is one of the most common complaints that leads to diagnosis, since a large mediastinal mass can compress airways or the lungs themselves.⁴ Chest pain, persistent cough, and a sense of pressure or fullness in the chest are also typical.

In some cases, the mass grows large enough to compress the superior vena cava, the major vein that drains blood from the head and arms back to the heart. This creates a condition called superior vena cava syndrome, which shows up as swelling of the face, neck, and arms, visible distension of veins in the chest and neck, and sometimes blood clots in the jugular vein.⁵ So-called B-symptoms, the classic trio of drenching night sweats, unexplained fevers, and significant weight loss, are also common at presentation and indicate the disease is provoking a strong systemic inflammatory response.

Because these symptoms overlap extensively with those of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, there is nothing about the clinical picture alone that points specifically to MGZL. The diagnosis only becomes clear when tissue is examined by an experienced hematopathologist.

Why Getting the Right Diagnosis Is Difficult

MGZL is one of the more challenging diagnoses in hematopathology. The transitional morphology, the mix of Reed-Sternberg-like cells alongside more typical large B-cells, and the variable expression of markers like CD20, CD30, and CD15 can lead to different pathologists reaching different conclusions on the same biopsy.⁶ One pathologist might call a case nodular sclerosis Hodgkin lymphoma; another might call it primary mediastinal large B-cell lymphoma; a third, recognizing the overlap, might render the gray zone diagnosis.

This disagreement is not a sign of incompetence. The underlying biology genuinely sits on a spectrum. Expert review, ideally at a center that sees a high volume of lymphomas, is strongly recommended for anyone whose initial biopsy raises the possibility of MGZL. A core-needle biopsy alone may not provide enough tissue for a confident diagnosis; excisional or incisional biopsy is preferred when feasible because it preserves the architecture of the tumor, which is a critical part of distinguishing MGZL from its look-alikes.

Staging follows the same playbook used for other lymphomas: PET-CT scanning to identify all sites of disease, bone marrow biopsy, and standard blood work. One emerging tool that has shown promise across many lymphoma types is circulating tumor DNA, fragments of tumor-derived genetic material detectable in the blood. While not yet standard practice in MGZL specifically, this approach could eventually help with diagnosis, treatment monitoring, and detection of relapse.⁷

Genetic Landscape and What It Reveals

Recent genetic profiling has begun to explain why MGZL behaves differently from its parent diseases. The most common mutations in cases with a mediastinal mass involve genes that also turn up frequently in Hodgkin lymphoma and primary mediastinal B-cell lymphoma, including SOCS1 and B2M (each mutated in about 45% of cases), as well as TNFAIP3, GNA13, and NFKBIA.⁸ Many of these genes are involved in immune evasion and the NF-κB signaling pathway, a cellular communication system that promotes cell survival and inflammation.

An interesting wrinkle emerged from that same mutational analysis: gray zone lymphomas arising outside the mediastinum had a markedly different genetic profile, with more mutations in genes controlling programmed cell death (like TP53 and BCL2) and fewer mutations in the NF-κB and immune-evasion genes that define the mediastinal form. This genetic distinction reinforces the decision by classification systems to treat mediastinal and non-mediastinal gray zone disease as separate entities. It also hints at why non-mediastinal cases may respond differently to treatment, though this remains an active area of investigation.

Frontline Treatment

Because MGZL is too rare for large randomized trials, treatment strategies have been borrowed from its two parent diseases and adapted based on smaller retrospective and prospective studies. The two main approaches are Hodgkin-directed chemotherapy (typically ABVD) and aggressive B-cell lymphoma-directed chemotherapy. The most studied regimen specifically in MGZL is DA-EPOCH-R, a dose-adjusted combination that includes rituximab, an antibody targeting the CD20 protein present on most MGZL tumor cells.

A study of 44 patients found that those who received DA-EPOCH-R as their initial treatment had a two-year progression-free survival of about 71%, compared with roughly 48% for patients treated with other regimens. Two-year overall survival was 93% with DA-EPOCH-R versus 79% with alternatives. On multivariate analysis, receiving DA-EPOCH-R up front was independently associated with better progression-free survival.⁹ These results have made DA-EPOCH-R the most commonly recommended frontline option at many centers, though some oncologists still favor R-CHOP (another B-cell-directed regimen) or ABVD, particularly when the morphology leans heavily toward Hodgkin lymphoma.

One practical challenge with DA-EPOCH-R is that it requires continuous intravenous infusion over several days per cycle, which is more cumbersome for patients than the single-day infusions of ABVD or R-CHOP. Still, the survival advantage in available data makes a strong case for the added inconvenience.

The Role of Radiation Therapy

Radiation to the mediastinum has long been part of treatment for both Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, so its use in MGZL is logical. The question is when radiation helps most. A study examining this found that, across all patients, adding radiation after chemotherapy did not produce a statistically significant improvement in two-year event-free survival overall (33% with radiation versus 23% without). However, the picture changed in specific subgroups. Patients who achieved only a partial response to chemotherapy saw a meaningful benefit from consolidation radiation, with a two-year event-free survival of 17% compared with 0% for those who skipped it. Patients with a suboptimal early response on imaging also benefited, as did those with bulky mediastinal disease.¹⁰

The takeaway from these data is that radiation after chemotherapy is most valuable for patients whose tumors do not respond completely to initial treatment. For patients who achieve a clean PET scan after chemotherapy, the role of radiation is less clear, and the potential long-term side effects of chest irradiation deserve serious weight in the decision. Mediastinal radiation is associated with a dose-dependent increase in the risk of heart disease later in life, particularly when the average dose absorbed by the heart exceeds a certain threshold.¹¹ Given that MGZL patients are often young, this is a significant consideration.

When the Disease Comes Back

Roughly a quarter to a third of MGZL patients experience primary refractory disease or early relapse within the first year.¹² For those patients, high-dose chemotherapy followed by autologous stem cell transplant is the standard salvage strategy, borrowing directly from the approach used in relapsed Hodgkin lymphoma and aggressive B-cell lymphomas. A multicenter U.S. study of this approach in gray zone lymphoma reported three-year progression-free and overall survival rates of about 69% and 78%, respectively, suggesting that a substantial fraction of relapsed patients can still achieve durable remissions.¹³ Longer-term follow-up data from single institutions support the durability of these responses, with many transplanted patients remaining in remission at five and even ten years.¹⁴

The development of targeted therapies has added promising options for patients whose disease is refractory to conventional chemotherapy. A combination of brentuximab vedotin, an antibody-drug conjugate that targets CD30, with nivolumab, a checkpoint inhibitor that blocks PD-1, showed impressive activity in a series of relapsed or refractory MGZL patients: the overall response rate was 70%, and half of those treated achieved a complete response. Half of the patients in that series were able to proceed to a consolidative stem cell transplant afterward.¹⁵ Checkpoint inhibitors used alone, such as pembrolizumab, have also produced complete metabolic responses in small case series.¹⁶ These results make biological sense given MGZL’s shared genetic features with Hodgkin lymphoma, where checkpoint inhibitors have become a cornerstone of relapsed-disease management.

What the Survival Numbers Actually Look Like

Survival statistics for MGZL vary considerably across studies, partly because different studies use different treatment regimens and different criteria for identifying cases. A prospective study with a median follow-up of about five years reported event-free survival of 62% and overall survival of 74%.¹⁷ A large multicenter cohort study reported a two-year overall survival of 88%, though two-year progression-free survival was lower at 40%, reflecting the relatively high early relapse rate.¹⁸

The gap between overall survival and progression-free survival is a recurring theme in MGZL data. Many patients who relapse can still be salvaged with transplant or newer therapies, so the overall survival numbers are meaningfully better than the progression-free numbers might suggest. The disease is aggressive and often recurs, but it is also frequently responsive to second-line treatment.

Several factors appear to predict worse outcomes. In the prospective study mentioned above, patients with a low absolute lymphocyte count in their blood at diagnosis had substantially worse event-free and overall survival compared with those whose lymphocyte counts were above the median. Strong expression of CD15 on tumor cells was also associated with poorer prognosis.¹⁷ In the multicenter cohort, performance status and stage at diagnosis were the strongest independent predictors of survival, which tracks with what is known in lymphoma generally.¹⁸

MGZL in Children and Adolescents

MGZL is extremely rare in pediatric patients. A study examining the overlap between primary mediastinal large B-cell lymphoma and MGZL in children and adolescents concluded that the gray zone diagnosis is so uncommon in this age group that it is unlikely to account for a significant portion of treatment failures in pediatric lymphoma protocols.¹⁹ When it does occur, it tends to present in older adolescents, with a median age around 16 in one small case series. All six patients in that series had advanced disease with mediastinal and extranodal involvement. Most were treated with aggressive B-cell-directed chemotherapy, and while initial responses were sometimes incomplete, three of the five patients given that approach survived, including two who relapsed and were salvaged with high-dose chemotherapy and autologous stem cell rescue.²⁰

The rarity of pediatric MGZL means there are no dedicated treatment guidelines for this age group. Clinicians typically adapt adult protocols, weighing the intensity of chemotherapy against the long-term risks of exposing a developing body to aggressive treatment. Referral to a pediatric cancer center with experience in rare lymphomas is particularly important.

Living After Treatment

Survivors of MGZL face many of the same long-term challenges as survivors of Hodgkin lymphoma and other mediastinal cancers, largely because the treatments overlap. The cardiac risk from mediastinal radiation has already been noted; it follows a dose-response curve, meaning more radiation to the heart translates to more risk of heart disease years or decades later.¹¹ Anthracycline-based chemotherapy regimens, which include drugs like doxorubicin, carry their own cumulative cardiac toxicity. Patients who receive both chest radiation and anthracyclines have a compounded risk, making long-term cardiovascular monitoring essential.

Secondary cancers are another concern. Radiation to the chest, especially in young women, increases the risk of breast cancer in later years. Lung cancer risk also rises. Guidelines for Hodgkin lymphoma survivors generally recommend earlier and more frequent cancer screening than the general population, and MGZL survivors who receive similar treatments should follow the same surveillance protocols.

Beyond the physical sequelae, the psychosocial toll of a cancer diagnosis in young adulthood is substantial. A registry study of adolescent and young adult lymphoma survivors found that they reported significantly worse quality of life compared to their healthy peers across multiple domains: physical functioning, emotional well-being, cognitive function, social engagement, fatigue, and financial difficulties.²¹ Financial toxicity is an underappreciated dimension: aggressive treatment during the years when most people are launching careers can create economic ripple effects that persist long after the disease itself is in remission. Survivorship care for MGZL should address not just physical monitoring but psychological support, fertility preservation counseling (ideally before treatment begins), and connection with resources for financial and vocational rehabilitation.

Separating MGZL from Its Look-Alikes

Even among expert pathologists, the boundary between MGZL and its two parent diseases sparks debate. A workshop held by the European Association for Haematopathology specifically devoted a session to this diagnostic territory, presenting cases that illustrated how difficult it can be to draw a clean line between MGZL, primary mediastinal large B-cell lymphoma, and Hodgkin lymphoma.²² One of the key unresolved questions is whether some cases currently classified as MGZL are really just unusual-looking versions of one parent disease, and whether treatment outcomes would be different if those patients had been classified differently from the start.

This uncertainty has practical consequences. If your biopsy is read as Hodgkin lymphoma, you receive ABVD or a related regimen. If it is read as primary mediastinal large B-cell lymphoma, you receive R-CHOP or DA-EPOCH-R. If it is read as gray zone lymphoma, the optimal choice is less clear. Misclassification in either direction could mean receiving a less-than-ideal regimen. This is one of the strongest arguments for seeking a second pathology opinion at a specialized center, particularly if the initial read is equivocal or if the clinical response to initial therapy is unexpectedly poor.

Gene expression profiling and mutational analysis may eventually resolve some of these borderline cases by placing tumors on a molecular spectrum rather than forcing a binary choice between two diagnostic buckets. For now, though, pathology remains a human judgment call, and that judgment call meaningfully influences treatment decisions. If you or someone you know has been given this diagnosis, understanding that the diagnostic process itself has genuine uncertainty built in can help frame conversations with the treatment team about why second opinions and expert review matter.